Loading clinical trials...
Loading clinical trials...
The Effects of an Exercise and Diet Intervention on Cardiovascular Risk Factors in Postmenopausal Type 2 Diabetics
Type 2 diabetics (non-insulin-dependent) are more than five times as likely to suffer an initial myocardial infarction (MI; heart attack) compared to nondiabetics.Female diabetics in particular, have a higher mortality rate for coronary artery disease (CAD) than male diabetics.C-reactive protein measurement in the clinical setting enhances the detection of individuals who are at high risk for cardiovascular disease (CVD), by providing additional predictive value. We propose to study the effects of a supervised exercise and diet intervention on cardiovascular disease risk in postmenopausal diabetic women. We will recruit 35 postmenopausal, sedentary type 2 diabetics who will undergo a 3 month exercise and dietary intervention. They will exercise 3 times a week for 30 min in a supervised setting. Exercise mode will be aerobic and self-selected (i.e. treadmill, bike) at an intensity level of 50-85% VO2peak. Blood glucose will be monitored before and after exercise. The dietary intervention will consist of 6 meetings with a registered dietitian. The study is designed to test the following hypotheses: * Cardiovascular disease risk measures will be different following a 3-month exercise and diet intervention. * H1: Blood markers for coronary artery disease risk, as measured by CRP, TC, LDL, TG, FG, fasting insulin, and HbA1c, will be different following a 3-month exercise and diet intervention. * H2: Anthropometric measures of coronary artery disease risk, as measured by WHR, will be different following a 3-month exercise and diet intervention. * H3: Resting blood pressure, as measured by SBP and DBP, will be different following a 3-month exercise and diet intervention. * H4: Total body fat, as measured by DXA, will be different following a 3-month exercise and diet intervention. * Health-related measures will be different following a 3-month exercise and diet intervention. * H1: Cardiorespiratory fitness, as measured by maximal oxygen consumption (VO2max) will be different following a 3-month exercise and diet intervention. * H2: Bone-mineral density, as measured by DXA, will be different following a 3-month exercise and diet intervention. * H3: Dietary measures (total daily kcal, and daily fat kcal) will be different following a 3-month exercise and diet intervention.
* Recruitment: Participants who have signed up for the research recruitment mailing list at the UCSF/Mt. Zion Osteoporosis Center will be mailed a CHR approved recruitment letter that briefly describes the study purpose and eligibility criteria. Only the individual's name and address are on the mailing list; there is no medical information. Medical records are not accessed. Telephone screening will take place in the ESS Department at USF. A script will be followed. * Pre and Post-Testing: Interested subject candidates will be scheduled to meet with Dr. Orri or Dr. Thompson at USF to provide written informed consent and complete a health history questionnaire (see appendix) to evaluate their CV risk. They will obtain written medical notification from their physician stating that they are in adequate diabetic control and cleared to begin an exercise program. Once selected, measurements of HT, WT, WHR, SBP, and DBP will take place in the ESS lab at USF. * Blood draws: Subjects will arrive at the UCSF GCRC after a 12-hr fast. The blood variables obtained will include: CRP, TC, LDL-C, HDL-C, TG, FG, fasting insulin (HOMA calculated for marker of insulin resistance), and HbA1c. Approximately 2 tablespoons of blood will be drawn. * Bone mineral density: BMD measurements (dual X-ray absorptiometry, DXA) will take place at the General Clinical Research Center at UCSF following the blood draw. A snack will be provided to the subjects prior to entering the DXA scanning area. * Cardiorespiratory fitness: Maximal exercise testing will be using a treadmill protocol in the Exercise Physiology Laboratory at UCSF General Clinical Research Center. Tests will be conducted by Dr. Orri, Dr. Thompson, and Joanne Krasnoff, M.S. The Naughton protocol will be used in which the grade is increased 3.5% every 2 min, while the speed remains at 2 mph after the warmup. The subject continues until volitional exhaustion or the exercise technicians terminate test end as designated by the American College of Sports Medicine (ACSM). All participants will have a 12-lead electrocardiogram (ECG) during the testing sessions to monitor for dysrhythmias or ischemia. Heart rate and blood pressure will be monitored every 2 minutes. Rating of perceived exertion (RPE) will be assessed every minute of the test. Maximal oxygen uptake (VO2max), as well as maximal levels of blood pressure, heart rate, respiratory exchange ratio (RER), and RPE will be recorded at the end of the test and used to determine the exercise training intensity. Expired gases will be collected throughout the test with CO2 and O2 and volume analyzed for calculation of oxygen uptake using a Quinton QMC computerized gas analysis system (Quinton Instruments, Bothell WA). All exercise technicians will be CPR and first-aid certified. * Body composition and BMD: Per cent body fat (%BF) and BMD will determined using dual energy X-ray absorptiometry (DXA). All scans will be done on a GE-Lunar Prodigy (Madison, WI). Variables of interest from the DXA scan will be %BF, total fat mass, lean body mass (LBM), and bone mineral density in g/cm2. * Exercise intervention: The 3-month exercise intervention will take place at the Millberry Union fitness center at UCSF, times per week for 30 min each session, accompanied by certified fitness professional who is trained to work with special populations. All standard emergency procedures will be followed by the trained UCSF staff. * Exercise program design: Study participants will be required to complete 36 exercise sessions in the 12 week program. They will exercise a minimum of 3 times per week for 30 min, accompanied by certified fitness professional who is trained to work with special populations. Participants will wear a HR monitor and be instructed to maintain an intensity in the range of 50-85% VO2peak obtained through max testing. During the initial phase of training (first 4 weeks), participants who are unable to exercise continuously for 30 minutes will perform intermittent exercise bouts of 10 minutes followed by 5 min of rest. Mode of exercise will be self-selected and will involve large muscle groups, incorporating any combination of the following machines: treadmill, stationary cycle, elliptical, Stairmaster, or rowing ergometer. * Blood glucose monitoring: Participants will be instructed to consume a snack 30-60 min before exercise. Prior to beginning each exercise session, all subjects will monitor their blood glucose to verify that it is between 100 and 250 mg/dl, in the absence of hypo/hyperglycemic symptoms (6). In addition, subjects will be monitored for 30 min post-exercise to verify that their BG is \> 70 mg/dl. Juice and protein snacks (peanut butter \& crackers) will be available to the subjects in case of post-exercise hypoglycemia. The exercise supervisor will be aware of those subjects who are taking medications that promote insulin production and will carry a glucagon pen. Late-evening exercise sessions will be avoided in order to prevent nocturnal hypoglycemia. * Dietary intervention: The subjects will receive six 30-min nutrition group counseling sessions with a dietitian. Sessions 1 and 6 will involve instruction on preparing 3-day dietary logs, while sessions 2-5 will consist of selected topics (i.e. dietary recommendations, low sodium diets, blood glucose control).
Age
45 - 75 years
Sex
FEMALE
Healthy Volunteers
Yes
University of California, San Francisco
San Francisco, California, United States
Start Date
June 1, 2006
Completion Date
May 1, 2007
Last Updated
August 16, 2007
35
ESTIMATED participants
3-month Exercise Training and Diet Education
BEHAVIORAL
Lead Sponsor
University of San Francisco
Collaborators
NCT06909773
NCT06505109
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06189313